logo

For the Inventor, By the Inventor

Yokohama, Japan

Seiji Shibahara

This inventor holds 44 USPTO granted patents, primarily in Antibiotic Derivatives. Top assignees: Meiji Seika Kaisha, Ltd., Meiji Seika Kabushiki Kaisha, Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai. Active years: 1981-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Seiji Shibahara. Retrieved from https://idiyas.com/inventor/seiji-shibahara

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 44

% Patents Active = 97.7

Average Co-Inventor Count = 6.7

ph-index = 7

Forward Citations = 177(Granted Patents)


Location History:

  • Tsukushino, Machida-shi, Tokyo, JP (1985)
  • Machida, JP (1984 - 1997)
  • Kanagawa, JP (1994 - 1997)
  • Kanagawa-ken, JP (1997)
  • Yokohama, JP (1989 - 1998)
  • Tokyo, JP (1981 - 2012)

Company Filing History:

goldMedal29 out of 382 
 
Meiji Seika Kaisha, Ltd.
 patents
silverMedal6 out of 32 
 
Meiji Seika Kabushiki Kaisha
 patents
bronzeMedal5 out of 212 
 
Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai
 patents
4. 3 out of 4,770 
 
Merck + Co., Inc.
 patents
5. 1 out of 2 
 
Forest Research Institute Malaysia
 patents
6. 1 out of 6 
 
Koichi Shudo
 patents
7. 1 out of 1 
 
Meiji Seika Kaburhiki Kaisha
 patent
8. 1 out of 4 
 
Nimura Genetic Solutions Co., Ltd.
 patents
9. 2 out of 834,513 
Other
 patents
where one patent can have more than one assignee

Years Active: 1981-2012

Loading Chart...
Areas of Expertise:
Antibiotics
Cephalosporin Derivatives
Macrolide Derivatives
Oxamic Acid Compounds
Benzoxazole Derivatives
Dibekacin Derivatives
Actinonin Derivatives
Thiazole Derivatives
Pyrrolidin-2-ylcarbonyl Compounds
Azole Derivatives
Antibacterial Agents
Pharmaceutical Compositions
44 patents (USPTO):Explore Patents
1. 8318684 - Antibiotics, bispolides A1, A2, and A3 as well as bispolides B1, B2a, B2b and B3 and processes for producing said antibiotics (2012-11-27),
2. 5849797 - D-.beta.-lysylmethanediamine derivatives and preparation thereof (1998-12-15),
3. 5827845 - Cephalosporin derivative (1998-10-27),
4. 5747448 - Derivatives of cyclodepsipeptide PF 1022 (1998-05-05),
5. 5663162 - Cephem derivatives (1997-09-02),
6. 5631257 - Benzoxazole derivatives (1997-05-20),
7. 5618795 - Dibekacin derivatives and arbekacin derivatives active against resistant (1997-04-08),
8. 5607927 - Cephalosporin derivative (1997-03-04),
9. 5602106 - 16-membered macrolide derivatives (1997-02-11),
10. 5547978 - Derivatives of pyrrolidin-2-ylcarbonylheterocyclic compounds (1996-08-20),
11. 5519122 - 16-membered macrolide derivatives and process for producing the same (1996-05-21),
12. 5488038 - Dibekacin derivatives and arbekacin derivatives active against resistant (1996-01-30),
13. 5464829 - Cephalosporin derivatives (1995-11-07),
14. 5461044 - Cephalosporin derivatives (1995-10-24),
15. 5444174 - 16-membered macrolide derivative having sustained antibacterial activity (1995-08-22),

Title: Innovations by Seiji Shibahara: A Pioneer in Antibiotics

Introduction

Seiji Shibahara, based in Yokohama, Japan, is an accomplished inventor with a remarkable portfolio of 44 patents. His work primarily focuses on developing novel antibiotic substances that address critical health challenges posed by bacterial infections, particularly those caused by Gram-positive bacteria.

Latest Patents

Among Shibahara's latest innovations are a series of antibiotics known as bispolides A1, A2, A3, B1, B2a, B2b, and B3. These antibiotics have been derived from a unique microbial strain isolated from soil, designated as strain A 34030. This strain, deposited under the access number FERM BP-10505 in accordance with the Budapest Treaty, has led to the discovery of seven distinct antibiotic substances. Each of these bispolides exhibits significant antibacterial activity against various bacteria and is particularly effective against antibiotic-resistant strains of Gram-positive bacteria. This innovation opens new therapeutic options for treating bacterial infections in both humans and animals.

Career Highlights

Throughout his career, Shibahara has worked with notable organizations, including Meiji Seika Kaisha, Ltd. and Meiji Seika Kabushiki Kaisha. His contributions have greatly advanced the field of pharmaceuticals, particularly in the development of antibiotic compounds that offer new solutions for combating resistant bacterial strains.

Collaborations

Seiji Shibahara has collaborated with distinguished colleagues such as Tsuneo Okonogi and Shinichi Kondo. These partnerships have enriched his research endeavors, leading to the successful development of innovative antibiotic substances that reflect the collaborative spirit of scientific exploration.

Conclusion

Seiji Shibahara stands out as a significant figure in the field of antibiotic research and development. His extensive list of patents underlines his commitment to innovation and his contributions to combating bacterial infections through novel antibiotic substances. His ongoing work continues to inspire future advancements in medical treatments and therapeutic interventions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…